XS 003 - XellSmart Biomedical (Suzhou)
Alternative Names: XS-003 - XellSmart Biomedical (Suzhou); XS_003Latest Information Update: 29 Dec 2023
At a glance
- Originator XellSmart Biomedical (Suzhou)
- Class Gene therapies; Induced pluripotent stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Brain injuries
Most Recent Events
- 19 Dec 2023 Preclinical trials in Brain injuries in China (Parenteral), prior to December 2023 (XellSmart Biomedical (Suzhou) pipeline, December 2023)